LFA102: CLFA102X2102: A phase I, multicenter, open-label study of LFA102 administered intravenously in patients with prolactin receptor-positive castration-resistant prostate cancer or prolactin receptor-positive metastatic breast cancer

Primary objectives
Dose Escalation:
1. To determine the MTD or RP2D of LFA102 as a single agent when administered I.V. to adult patients with prolactin receptor-positive castration
resistant prostate cancer (CRPC) or metastatic breast cancer (MBC)
Dose Expansion:
1. To characterize the safety and tolerability of LFA102, including both acute and chronic toxicities
Secondary objectives
1. To characterize single and multiple dose PK of LFA102
2. Prostate cancer: To assess preliminary anti-tumor activity of
LFA102 as a single agent when administered IV to adult patients with prolactin receptor-positive CRPC
3.Breast cancer: To assess preliminary anti-tumor activity of LFA102 as a single agent when administered I.V to adult patients with PRLR-positive MBC
4. To assess any emergence of anti-LFA102 antibodies

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.